

# **ArTec, Inc., Of Reno, Nevada Announces Completing Its Patent Goals and Has Received the Final Patents from Canada and Western Europe That Were Pending**

Monday September 27, 5:00 am ET

RENO, Nev.--(BUSINESS WIRE)--Sept. 27, 2004--ArTec, Inc., (Pink Sheets: ATKJ - News ) A Pharmaceutical Company announces completing its patent goals and receiving the final patents from Canada and Western Europe. On August 13, 2003, the Western European Patent consisting of United Kingdom, France, Spain, Germany and Italy was issued. On May 11, 2004, the patent from Canada was issued. The goals accomplished consist of five final Patents that ArTec, Inc. will utilize:

1. Canada patent issued May 11, 2004, registration number 2,293,821.
2. Western Europe patent issued August 13, 2003, registration number 0,991,773.
3. United States patent issued August 14, 2001, registration number 6,274,356.
4. South Korea patent issued October 29, 1998, registration number 173362.
5. Japan patent issued June 12, 1998, registration number

2,790,447.

Dr. Tai Ho Chung, M.D. Ph.D., Principal Partner and Scientific Advisor for ArTec, Inc. denotes "that having acquired, all five patents now allows ArTec, Inc. to focus on US FDA submission." Furthermore, he is encouraged by the fact that research is complete (Finished Product) and there have been no adverse side effects in human and mice studies using Tubercin on CANCER. Upon raising funds, ArTec, Inc. will move quickly into US FDA submission.

What is Tubercin?

The United States Patent issued August 14, 2001, states in the abstract summary the following:

"A carbohydrate complex, which is a mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted from Mycobacterium tuberculosis, is highly effective in treating various cancer patients without incurring any adverse side effects." For further information, the US Patent and Trademark Offices's Official web site can be retrieved from ArTec, Inc.'s web site at [www.artec-inc.net](http://www.artec-inc.net) .

Forward-looking statements in this press release, the company cautions the investors, involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

ArTec, Inc. A Pharmaceutical Company whose goal is to improve the quality of life!